SIRT3 and carcinoma: In noncancerous samples the majority (56%, 19/32) was SIRT3-high scored, whereas in carcinoma samples, the percentage of SIRT3-high scored plummeted to 22% (16/74) with the SIRT3-low scored rising up to 58% (43/74) (Figure 1D).